Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Upcoming, not missing, posts...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(40)
•••
Comment by zwerp2000on Sep 22, 2021 11:42am
150 Views
Post# 33898423

RE:RE:RE:Upcoming, not missing, posts...

RE:RE:RE:Upcoming, not missing, posts...For years the company has been telling shareholders how promising the pre-clinical data has been and yet nothing in the clinic? It's enough with the hype on their pre-clinical data. Get it into clinic. As for Chiasi, the deal was signed well over 1 year ago and no updates? The deal with Prothena was signed several years ago and the program has really gone nowhere. If there was something there, it would be moving forward. The company has done very little to move its pipeline forward and instead, uses the same fluff, much life JD does, to pump its stock. The stock is near a 52 week low. If i told you 10 years ago that in 10 years, the company's stock would be this low, there would be no drugs in the clinic and that they'd really have no partnerships of substance, and that they'd still be just hyping pre-clinical data, you'd be extremely disappointed, no?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities